Skip to main content

Advertisement

Table 1 Characteristics of the RP patients used for qMSP

From: Epigenetic silencing of MEIS2 in prostate cancer recurrence

Variable qMSP cohort (n = 195 PC patients)
Age at RP, median (range) 64 (49–77)
Pre-operative PSA (ng/mL), median (range) 13 (2.1–284.0)
Pathological Gleason Score
 < 7, n (%) 64 (32.8)
 = 7, n (%) 94 (48.2)
  3 + 4, n (%) 86 (91.5)
  4 + 3, n (%) 8 (8.5)
 > 7 n (%) 35 (18.0)
 Unknown, n (%) 2 (1.0)
Pathological T-stage
 ≤ pT2c, n (%) 126 (64.6)
 ≥ pT3a, n (%) 67 (34.4)
 Unknown, n (%) 2 (1.0)
Pathological N-stage
 pN0, n (%) 167 (85.6)
 pN1, n (%) 15 (7.7)
 pNX/unknown, n (%) 13 (6.7)
Surgical margin status
 Negative margin, n (%) 135 (69.2)
 Positive margin, n (%) 56 (28.7)
 Unknown, n (%) 4 (2.1)
CAPRA-S score
 0–2 54 (27.7)
 3–5 77 (39.5)
 6–10 50 (25.6)
 Unknown 14 (7.2)
Follow-up (months), median (range) 131 (12–219)
 No PSA recurrence, n (%) 88 (45.1)
 PSA recurrence, n (%) 104 (53.3)
 Unknown, n (%) 3 (1.6)
Variable AN (n = 17) BPH (n = 6)
Age at RP, median (range) 65 (56–73) 67 (56–73)